Keros Therapeutics Updates on Clinical Trials and Safety

Keros Therapeutics ( (KROS) ) has provided an announcement.

Keros Therapeutics announced updates to its corporate presentation, highlighting ongoing and future clinical trials for its product candidates, including cibotercept (KER-012) for pulmonary arterial hypertension. The company has halted dosing in certain treatment arms of the TROPOS trial due to safety concerns but continues with others, aiming to report trial data in 2025, which could impact its clinical development program and industry positioning.

More about Keros Therapeutics

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for disorders linked to dysfunctional TGF-β superfamily signaling. The company is working on product candidates designed to modulate TGF-β signaling, targeting pathways critical for tissue and organ system growth, repair, and maintenance.

YTD Price Performance: -6.47%

Average Trading Volume: 909,924

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $603.2M

For an in-depth examination of KROS stock, go to TipRanks’ Stock Analysis page.